Synthesis, characterization, X-ray crystal structure and in vitro antitumour activity of sodium bis(2-(3′,6′,9′-trioxadecyl)-1,2-dicarba-closo- dodecaborane-1-carboxylato)triphenylstannate

被引:11
作者
Bregade, VI
Glazun, SA
Petrovskii, PV
Starikova, ZA
Buyanovskaya, AG
Takazova, RU
Gielen, M
de Vos, D
Kemmer, M
Biesemans, M
Willem, R
机构
[1] RAS, AN Nesmeyanov Inst Organoelement Cpds, Moscow 119991, Russia
[2] Free Univ Brussels, High Resolut NMR Ctr, Dept Polymer Sci & Struct Chem, B-1050 Brussels, Belgium
[3] PCH Nederland, Dept Med, NL-2300 RN Haarlem, Netherlands
关键词
organotin carboranecarboxylate; synthesis; crystal structure; antitumour activity;
D O I
10.1002/aoc.599
中图分类号
O69 [应用化学];
学科分类号
081704 ;
摘要
Sodium bis[2-(3',6',9'-trioxadecyl)-1,2-dicarba-closo-dodecaborane-1-carboxylato]triphenylstannate, [(CH3OCH2CH2OCH2CH2OCH2CH2)-1,2-C2B10H10-9-COO)(2)SnPh3](-) Na+, compound 1, was synthesized by the 1:1 condensation of triphenyltin(IV) hydroxide with 2-(3,6',9'-trioxadecyl)-1,2-dicarbacloso-dodecaborane-1-carboxylic acid and crystallized in the presence of sodium bicarbonate. Its structure was determined by spectroscopy, elemental analysis and X-ray diffraction. The structure of 1 consists of trigonal bipyramidal [Sn(Ph)(3)(L)(2)](-) anions and Na+ cations coordinated by oxygen atoms of polyoxaalkyl chains of different stannate anions, forming cation-anion chains elongated along the c axis. Compound 1 is significantly more active in vitro against seven tumour cell lines of human origin than 5-fluorouracil, cis-platin, carboplatin, and previously reported organotin carboranecarboxylates, but is less active than organotin polyoxaalkylcarboxylates. Copyright (C) 2004 John Wiley Sons, Ltd.
引用
收藏
页码:191 / 194
页数:4
相关论文
共 22 条
[1]  
Allen MW, 2000, ADV PSY RES, V1, P31
[2]  
BOUALAM M, 1991, MAIN GROUP MET CHEM, V14, P41
[3]   Synthesis, characterization, X-ray crystal structure and in vitro antitumour activity of bis(1,2-dicarba-closo-decaborane-9-carboxylato)di-n-butyltin [J].
Bregadze, VI ;
Glazun, SA ;
Petrovskii, PV ;
Starikova, ZA ;
Rochev, VY ;
Dalil, H ;
Biesemans, M ;
Willem, R ;
Gielen, M ;
de Vos, D .
APPLIED ORGANOMETALLIC CHEMISTRY, 2003, 17 (6-7) :453-457
[4]   DICARBA-CLOSO-DODECABORANES C2B10H12 AND THEIR DERIVATIVES [J].
BREGADZE, VI .
CHEMICAL REVIEWS, 1992, 92 (02) :209-223
[5]  
*BRUK AXS INC, 1998, SAINT V5 00 AR DET C
[6]  
DeVita VT., 1997, CANC PRINCIPLES PRAC, V5th
[7]  
GELMAN NE, 1987, METHODS QUALITY ORGA, P293
[8]  
Gielen M, 1995, Met Based Drugs, V2, P37, DOI 10.1155/MBD.1995.37
[9]   Organotin compounds and their therapeutic potential: a report from the Organometallic Chemistry Department of the Free University of Brussels [J].
Gielen, M .
APPLIED ORGANOMETALLIC CHEMISTRY, 2002, 16 (09) :481-494
[10]   X-RAY STRUCTURE OF THE DIMERIC BIS[(1,7-DICARBA-CLOSO-DODECABORANE-1-CARBOXYLATO)-DI-N-BUTYLTIN] OXIDE [J].
GIELEN, M ;
BOUHDID, A ;
WILLEM, R ;
BREGADZE, VI ;
ERMANSON, LV ;
TIEKINK, ERT .
JOURNAL OF ORGANOMETALLIC CHEMISTRY, 1995, 501 (1-2) :277-281